Samyang Holdings Filler 'Rapullen' Enters China... Total Scale of 100 Billion KRW

Samyang Holdings is making a full-scale entry into the global beauty and plastic surgery market by exporting the biodegradable polymer filler ‘Lapullen’ to the Chinese market.

After the 'Lapullen' partnership contract ceremony held on the 24th at the Pangyo Samyang Discovery Center, Lee Young-jun, CEO of Samyang Holdings (left), and Evan Wang, Chairman of Eshin Tent, are taking a commemorative photo.
[Photo by Samyang Holdings]

On the 24th, Samyang Holdings’ Biopharm Group announced on the 25th that it signed a partnership agreement related to the export of Lapullen with Hangzhou Yxintent, a Chinese medical device and aesthetic specialist company, at the Samyang Discovery Center in Pangyo, Seongnam-si, Gyeonggi Province. Under this agreement, Yxintent will conduct clinical trials and obtain approval for Lapullen in China. After approval, it will have exclusive sales rights for Lapullen within China.

Through this contract, Samyang Holdings explained that it has become the first Korean company to enter the biodegradable polymer filler market in China. It will supply finished products worth approximately 100 billion KRW over the next five years. Through this, the company plans to secure a leading position in China’s rapidly growing polymer filler market every year.

Lapullen is a facial plastic surgery filler developed by Samyang Holdings’ Biopharm Group. The product name combines the German word ‘lauter,’ meaning ‘pure,’ and ‘f?llen,’ meaning ‘to fill or be full,’ conveying the meaning of ‘purely filling.’ Its main ingredient is polycaprolactone (PCL), a medical biodegradable polymer material, which maintains its effect for more than two years. Thanks to Samyang Holdings’ patented technology, it is said to cause less foreign body sensation and provide natural volume. It was approved in 2021, and research results proving its long-term effects and safety have been published in international academic journals.

Samyang Holdings’ Biopharm Group has been actively entering the global filler market for Lapullen, having obtained product approval in Indonesia last April. It is preparing for a local launch in Indonesia and is also discussing export contracts with multiple countries in Latin America and Southeast Asia.

Lee Young-jun, CEO of Samyang Holdings, said, “Yxintent has a large-scale approval specialist workforce and sales network, so we expect to obtain product approval in China soon and increase market share. Starting with Lapullen, we will gradually strengthen partnerships in the beauty and plastic surgery fields, including the lifting thread ‘Croquis.’”

Evan Wang, Chairman of Yxintent, also said, “Samyang Group is a company with a long history and excellent technology, and we have high expectations for Lapullen, which is the result of that technology. We will form a close partnership with Samyang Group to achieve approval and successful market entry in China for Lapullen.”

This content was produced with the assistance of AI translation services.